168 related articles for article (PubMed ID: 25232954)
1. Repurposed automated handheld counter as a point-of-care tool to identify individuals 'at risk' of serious post-ivermectin encephalopathy.
Bennuru S; Pion SD; Kamgno J; Wanji S; Nutman TB
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3180. PubMed ID: 25232954
[TBL] [Abstract][Full Text] [Related]
2. A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas.
Kamgno J; Pion SD; Chesnais CB; Bakalar MH; D'Ambrosio MV; Mackenzie CD; Nana-Djeunga HC; Gounoue-Kamkumo R; Njitchouang GR; Nwane P; Tchatchueng-Mbouga JB; Wanji S; Stolk WA; Fletcher DA; Klion AD; Nutman TB; Boussinesq M
N Engl J Med; 2017 Nov; 377(21):2044-2052. PubMed ID: 29116890
[TBL] [Abstract][Full Text] [Related]
3. Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.
Wanji S; Eyong EJ; Tendongfor N; Ngwa CJ; Esuka EN; Kengne-Ouafo AJ; Datchoua-Poutcheu FR; Enyong P; Agnew D; Eversole RR; Hopkins A; Mackenzie CD
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005576. PubMed ID: 28686693
[TBL] [Abstract][Full Text] [Related]
4. Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.
Pion SD; Nana-Djeunga H; Niamsi-Emalio Y; Chesnais CB; Deléglise H; Mackenzie C; Stolk W; Fletcher DA; Klion AD; Nutman TB; Boussinesq M; Kamgno J
Lancet Infect Dis; 2020 Jan; 20(1):102-109. PubMed ID: 31676244
[TBL] [Abstract][Full Text] [Related]
5. Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa.
Wanji S; Chounna Ndongmo WP; Fombad FF; Kengne-Ouafo JA; Njouendou AJ; Longang Tchounkeu YF; Koudou B; Bockarie M; Fobi G; Roungou JB; Enyong PA
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006750. PubMed ID: 30226900
[TBL] [Abstract][Full Text] [Related]
6. Microfilarial distribution of Loa loa in the human host: population dynamics and epidemiological implications.
Pion SD; Filipe JA; Kamgno J; Gardon J; Basáñez MG; Boussinesq M
Parasitology; 2006 Jul; 133(Pt 1):101-9. PubMed ID: 16764737
[TBL] [Abstract][Full Text] [Related]
7. [Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
Ducorps M; Gardon-Wendel N; Ranque S; Ndong W; Boussinesq M; Gardon J; Schneider D; Chippaux JP
Bull Soc Pathol Exot; 1995; 88(3):105-12. PubMed ID: 8555762
[TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of Loa loa Microfilaria-Specific Biomarkers: a Rational Design Approach Using Proteomics and Novel Immunoassays.
Drame PM; Meng Z; Bennuru S; Herrick JA; Veenstra TD; Nutman TB
mBio; 2016 Feb; 7(1):e02132-15. PubMed ID: 26884435
[TBL] [Abstract][Full Text] [Related]
9. Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp.
Kamgno J; Boussinesq M; Labrousse F; Nkegoum B; Thylefors BI; Mackenzie CD
Am J Trop Med Hyg; 2008 Apr; 78(4):546-51. PubMed ID: 18385346
[TBL] [Abstract][Full Text] [Related]
10. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.
Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Kamgno J; Chippaux JP; Boussinesq M
Lancet; 1997 Jul; 350(9070):18-22. PubMed ID: 9217715
[TBL] [Abstract][Full Text] [Related]
11. Co-infection with Onchocerca volvulus and Loa loa microfilariae in central Cameroon: are these two species interacting?
Pion SD; Clarke P; Filipe JA; Kamgno J; Gardon J; Basáñez MG; Boussinesq M
Parasitology; 2006 Jun; 132(Pt 6):843-54. PubMed ID: 16469200
[TBL] [Abstract][Full Text] [Related]
12. Evaluating post-treatment Loa loa microfilarial densities to classify serious adverse events caused by ivermectin: a retrospective analysis.
Boullé C; Chesnais CB; Kamgno J; Gardon J; Chippaux JP; Ranque S; Garcia A; Pion SD; Boussinesq M
Lancet Microbe; 2023 Feb; 4(2):e93-e101. PubMed ID: 36646105
[TBL] [Abstract][Full Text] [Related]
13. Loiasis is endemic in the Ndikinimeki Health District (Centre Region, Cameroon) but does not represent a hindrance to onchocerciasis elimination.
Sumo L; Ntonifor NH; Afor AR; Bopda J; Bamou Heumou R; Ondoua Nganjou GS; Nana Djeunga HC
Acta Trop; 2022 Jan; 225():106218. PubMed ID: 34755644
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of small animal models for onchocerciasis and loiasis microfilaricide discovery.
Ayiseh RB; Mbah GE; Monya E; Ndi EM; Sakanari J; Lustigman S; Cho-Ngwa F
PLoS Negl Trop Dis; 2023 Feb; 17(2):e0011135. PubMed ID: 36827447
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.
Bourguinat C; Kamgno J; Boussinesq M; Mackenzie CD; Prichard RK; Geary TG
Am J Trop Med Hyg; 2010 Jul; 83(1):28-32. PubMed ID: 20595473
[TBL] [Abstract][Full Text] [Related]
16. Projected Number of People With Onchocerciasis-Loiasis Coinfection in Africa, 1995 to 2025.
Vinkeles Melchers NVS; Coffeng LE; Boussinesq M; Pedrique B; Pion SDS; Tekle AH; Zouré HGM; Wanji S; Remme JH; Stolk WA
Clin Infect Dis; 2020 May; 70(11):2281-2289. PubMed ID: 31304961
[TBL] [Abstract][Full Text] [Related]
17. Co-endemicity of loiasis and onchocerciasis in the South West Province of Cameroon: implications for mass treatment with ivermectin.
Esum M; Wanji S; Tendongfor N; Enyong P
Trans R Soc Trop Med Hyg; 2001; 95(6):673-6. PubMed ID: 11816443
[TBL] [Abstract][Full Text] [Related]
18. Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis.
Twum-Danso NA; Meredith SE
Trop Med Int Health; 2003 Sep; 8(9):820-31. PubMed ID: 12950668
[TBL] [Abstract][Full Text] [Related]
19. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial.
Turner JD; Tendongfor N; Esum M; Johnston KL; Langley RS; Ford L; Faragher B; Specht S; Mand S; Hoerauf A; Enyong P; Wanji S; Taylor MJ
PLoS Negl Trop Dis; 2010 Apr; 4(4):e660. PubMed ID: 20405054
[TBL] [Abstract][Full Text] [Related]
20. Geostatistical modelling enables efficient safety assessment for mass drug administration with ivermectin in Loa loa endemic areas through a combined antibody and LoaScope testing strategy for elimination of onchocerciasis.
Johnson O; Giorgi E; Fronterrè C; Amoah B; Atsame J; Ella SN; Biamonte M; Ogoussan K; Hundley L; Gass K; Diggle PJ
PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010189. PubMed ID: 35139080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
